These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27817214)

  • 1. Antibody therapeutics for treating prostate cancer: where are we now and what comes next?
    Vlachostergios PJ; Galletti G; Palmer J; Lam L; Karir BS; Tagawa ST
    Expert Opin Biol Ther; 2017 Feb; 17(2):135-149. PubMed ID: 27817214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.
    Evans JC; Malhotra M; Cryan JF; O'Driscoll CM
    Br J Pharmacol; 2016 Nov; 173(21):3041-3079. PubMed ID: 27526115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
    Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
    Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.
    Bander NH; Nanus DM; Milowsky MI; Kostakoglu L; Vallabahajosula S; Goldsmith SJ
    Semin Oncol; 2003 Oct; 30(5):667-76. PubMed ID: 14571414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
    Wang X; Ma D; Olson WC; Heston WD
    Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen.
    Slovin SF
    Expert Opin Ther Targets; 2005 Jun; 9(3):561-70. PubMed ID: 15948673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.
    Huang CT; Guo X; Bařinka C; Lupold SE; Pomper MG; Gabrielson K; Raman V; Artemov D; Hapuarachchige S
    Mol Pharm; 2020 Sep; 17(9):3392-3402. PubMed ID: 32803984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
    Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
    Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapies for prostate cancer against the prostate specific membrane antigen.
    Elsässer-Beile U; Bühler P; Wolf P
    Curr Drug Targets; 2009 Feb; 10(2):118-25. PubMed ID: 19199907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.
    Bander NH; Trabulsi EJ; Kostakoglu L; Yao D; Vallabhajosula S; Smith-Jones P; Joyce MA; Milowsky M; Nanus DM; Goldsmith SJ
    J Urol; 2003 Nov; 170(5):1717-21. PubMed ID: 14532761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools.
    Nováková Z; Foss CA; Copeland BT; Morath V; Baranová P; Havlínová B; Skerra A; Pomper MG; Barinka C
    Prostate; 2017 May; 77(7):749-764. PubMed ID: 28247415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.
    Milowsky MI; Nanus DM; Kostakoglu L; Sheehan CE; Vallabhajosula S; Goldsmith SJ; Ross JS; Bander NH
    J Clin Oncol; 2007 Feb; 25(5):540-7. PubMed ID: 17290063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer.
    Hapuarachchige S; Huang CT; Donnelly MC; Bařinka C; Lupold SE; Pomper MG; Artemov D
    Mol Pharm; 2020 Jan; 17(1):98-108. PubMed ID: 31840521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA.
    Psimadas D; Valotassiou V; Alexiou S; Tsougos I; Georgoulias P
    Cancer Invest; 2018 Feb; 36(2):118-128. PubMed ID: 29393702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
    DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E
    Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
    Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC
    Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the prostate-specific membrane antigen for prostate cancer therapy.
    Bühler P; Wolf P; Elsässer-Beile U
    Immunotherapy; 2009 May; 1(3):471-81. PubMed ID: 20635963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles.
    Mirochnik Y; Rubenstein M; Guinan P
    J Drug Target; 2007 Jun; 15(5):342-50. PubMed ID: 17541843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
    Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
    Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies: will they become an integral part of the evaluation and treatment of prostate cancer--focus on prostate-specific membrane antigen?
    Chang SS; Bander NH; Heston WD
    Curr Opin Urol; 1999 Sep; 9(5):391-5. PubMed ID: 10579076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.